Genetic mutations associated with increased PSA and prostate cancer

	Tweet

Austrian researchers have uncovered mutations throughout the mitochondrial genome that are associated with prostate cancer. An exciting aspect of the study, published by Cell Press on December 2 in the American Journal of Human Genetics, is the association of tRNA mutations with elevated levels of prostate-specific antigen (PSA) in Austrian men diagnosed with various stages of prostate cancer.

Prostate cancer is among the most prevalent cancers diagnosed in the United States and Europe. The most common and noninvasive way to detect prostate cancer is to check PSA levels. This is a routine part of men’s health checks starting around the age of 50. Elevated PSA levels indicate the possibility of prostate cancer. Prostate biopsies are used for verification of PSA results and cancer diagnosis. Treatment may include surgery, radiation, or chemotherapy. “Identifying genetic variants associated with prostate cancer and its primary biomarker is an exciting accomplishment,” says Dr. Anita Kloss-Brandstätter, the lead author of this study.

Recognizing the important role mtDNA mutations have been found to play in development and progression of many types of cancer, Dr. Kloss-Brandstätter and colleagues set out to sequence the entire mitochondrial genome in 30 prostate cancer patients.

"The influence of mtDNA on the origin and progression of prostate cancer is still not understood, leaving much to be discovered,” says Dr. Kloss-Brandstätter. The group used a high-quality sequencing approach to detect differences in mtDNA sequence between cancerous and noncancerous tissue from the same 30 men. “It is the first study targeting the entire mitochondrial genome in prostate cancer and benign tissue from the same patient with a superior sequencing strategy,” notes Dr. Kloss-Brandstätter.

By examining both the frequency and types of somatic mtDNA mutations in prostate cancer patients, Dr. Kloss-Brandstätter and colleagues were able to identify several genetic changes having clinical significance. They suggest that, “sequencing of selected mitochondrial regions will likely result in a mutation spectrum useful for prognosis.” Perhaps the most striking finding of the study is the association between somatic tRNA mutations and PSA levels at diagnosis. “Patients with a somatic tRNA mutation had a significantly higher PSA value at diagnosis than did patients without a somatic tRNA mutation,” explains Dr. Kloss-Brandstätter. “These findings will potentially help others monitor malignant transformation, tumor progression, and metastasis,” she says.

###

Contact: Elisabeth (Lisa) Lyons

617-386-2121
Cell Press

RELATED STORIES:
‘Mismatched’ prostate cancer treatment more common than expected   No Evidence That Widely Prescribed Statins Protect Against Prostate Cancer   Variances in patterns of care for patients with prostate cancer failing primary therapy   New Web site Helps Doctors and Prostate Cancer Patients Make Better Treatment Choices   Soy compound may halt spread of prostate cancer   Not all cancer patients improve lifestyle   Prostate cancer increases hip fracture risk by eight times in 50 to 65 year-olds   Daily drinking may raise risk of several cancers   Scientists identify prostate cancer stem cells among low-PSA cells   Mediterranean Diet May Help Prevent Prostate Cancer   What is the role of focal therapy in low-risk prostate cancer?   Prostate surgery risks lower at academic hospitals   Many prostate cancer patients receive improper or ‘mismatched’ therapies   Gene Markers Located for Hereditary Prostate Cancer   Study Looks at Celebrex and Lipitor to Treat Prostate Cancer   Dehydrated tomatoes show promise for preventing prostate cancer   PSA screening declines following publication of large trials, guidelines   New drug targets vitamin D receptors in hormone resistant prostate cancers   Why African-American Men Are at Higher Risk for Prostate Cancer   New data show benefit of finasteride in preventing prostate cancer   Prostate cancer cost varies widely by treatment   Prostate cancer therapy linked to increased risk of heart disease death

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]